Ruti Aga's Six-Year Ban: How One Forged Prescription Destroyed the Defence Real Records Could Have Saved

The prescription carried the name of a clinic that did not exist. It carried the name of a doctor who held no medical registration — a family member of Ruti Aga. And when the investigating body reached that clinic, the answer came back that the "old prescription pad" had never belonged to it at all. Three verifications. Three denials. Not a single link that holds.

On Thursday the Athletics Integrity Unit (AIU) issued its statement, and the first number you notice is six — two years for the presence of a prohibited substance, four for tampering with the evidence presented to justify it. The ban on the 32-year-old Ethiopian marathoner runs from 10 September, the same date her provisional suspension began. All of it traces to one March race: a half marathon in China that she won, and for which no mark appears anywhere in the statement.

That absence is the first truth of this story. No personal best, no splits, no stadium, no crowd. Just a document, a family, and a substance that a large share of the reporting called by the wrong name.

Who Ruti Aga is, and which layer of her career this touches

Recall the 2026 Tokyo Marathon. Ruti Aga won it. That is not a small line — a prestigious World Marathon Major, won by a runner who never returned to that height. Public records list her best as roughly 2:18:34 for second in Berlin 2026, and about 2:20:40 for the Tokyo 2026 win. Those figures are not in the AIU statement, so read them as external record rather than as a claim in the notice. What the statement confirms is three second-place finishes at World Marathon Majors.

Ethiopia's women's marathon ceiling has climbed to a place where a 2:18 runner is not automatically selectable; the sub-2:12 world-record tier exists in the same squad pool. Aga belonged to the excellent, deeply professional 2:18–2:20 class that sits just under it. That matters for scale, and so does its inverse: Ethiopian depth is so extreme that the removal of a 2:18 athlete is nearly invisible at national-team level — and that invisibility is exactly what makes an ecosystem in which forged prescriptions happen possible.

The statement does not specify the tier of that March race in China. The logic is straightforward: if the AIU tested there, it was a World Athletics Label race with an international elite field and in-competition testing. This is the economic layer without which the case stays incomplete — for East African marathoners, China's label circuit is a large, comparatively low-risk income tier between Majors, and appearance fees are its main product. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are running on the same track.

In 2026 I called the Gold Coast Commonwealth Games from a bedroom in Hyderabad, watching Neeraj Chopra's 86.47 javelin on a screen while holding Krishna Poonia's 2026 discus gold in my head. From a bedroom I called that race and felt the circle meet the runway — two halves of the same memory. This case has two circles too. One holds the sporting record; the other holds the administrative cost of keeping that record standing. Nobody sits in the second one.

The real technical error: a substance that was never what it was called

Everything that follows rests on one sentence that most reports got wrong: methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List. Anabolic steroids sit in S1. Different chemistry, different mechanism, and — most importantly — different rule.

S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic injection given out of competition is entirely lawful. It becomes a violation only if residue is present in an in-competition sample. That single sentence flips the case: this is not a "steroid use" case. It is a route-and-timing case.

Now add road-race mechanics. A road race's in-competition testing window opens at 23:59 the night before. In plain terms: an injection into the knee days before a race whose residue survives into race day will be caught — even if the treatment was lawful and necessary. That technical point is the spine of the case, and it needs saying plainly that the "steroid" story attached to it does not exist in the pharmacology.

Why does the distinction matter? Because it changes which defence was open. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. A documented treatment, a date, a record, a route-and-timing explanation — a legitimate defence existed here. That plausibility is precisely what makes the forgery decisive. Real treatment would have been defended with real records.

The paper trail: three verifications, three denials

Lay out the account in the statement. A knee injury is cited — technically credible in high-volume marathoners. A prescription underpins the treatment. That prescription was written by a person with no medical registration, related to the athlete, who said he used "an old prescription pad from a former workplace." And the clinic named on that pad either does not exist or explicitly disowns the use of its name.

Three independent verification failures. This is not a filing error. It is the signature of an athlete operating without a credentialed team physician.

And a fourth, heavier point: the four-year tampering sanction arises from an interview, not from a document alone. From statements made under questioning. That distinction matters because language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention. That is not an allegation about this case; it is a general caution about the process. But when four years rest on statements, the language question stops being decorative.

One thing is absent from the statement, with no sign of investigation: whether any agent, manager or coach played a role in producing that prescription. How a family member arrived at that decision alone is unanswered. No athlete suddenly decides to invent a clinic.

The arithmetic of the sanction: two plus four, and the defence that did not survive

There is a strange clarity in counting. Two years for presence, four for tampering. The sum is a sentence in itself.

The arithmetic indicates the panel did not accept the no-fault or no-significant-fault mitigation that would have reduced the presence sanction — potentially to a reprimand. Two years for presence typically arrives when the substance is specified and intent was not proven. Four years for tampering is the Code's standard sanction, applied without discount, because fabricated evidence attacks the integrity of the process more directly than the substance does. This is inference, but inference built from the numbers.

Backdating to 10 September is no relief. Provisional suspension time counts against the ban, so the athlete gains nothing in real terms; it is a procedural benefit. The statement does not state the year explicitly, but the phrase "provisionally suspended since 10 September" indicates the current one.

An appeal path exists at CAS, typically within about 21 days of the reasoned decision. But a finding built on documents is the hardest kind to overturn. A forged prescription is not testimony that could have been garbled in translation; it is a physical object whose own source has disowned it.

Thirty-two now, thirty-eight on return

The age curve is simple arithmetic: 32 now, 38 after six years. A return at 38 is not impossible in women's marathon — it is close to impossible in Ethiopia, where better depth than you sits waiting every season and a doping record ends a selection conversation before it starts.

There is a judicial nuance here that gets lost in the rush. The violation is anchored to that March race. Absent a finding of earlier use, results before that date are not automatically annulled. Which means the 2026 Tokyo title and the three Major second places remain on the record. The statement does not describe the disqualification scope, and that silence is its loudest information: the March result will very likely be voided, and what came before it will not.

This returns me to a category I keep circling. In 2026, volunteering as PA announcer at the Telangana State Junior Athletics Meet, I mispronounced the boys' 100m winner's name three times — M. Srinivas, who had run 10.9 seconds on a dirt track. I interviewed him afterwards and learned he trained barefoot after school. I learned to pronounce my own name by hearing strangers get it wrong, and that habit tells me what will happen to Aga's Tokyo title. Five years from now, anyone searching her name will find the six-year ban first, not the 2:20. The first entry in the record book is the one that gets remembered.

This is where Patiala taught me something. In 2026 I called a behind-closed-doors Indian Grand Prix meet from college radio, and 17-year-old Kerala middle-distance runner P. M. Anjali ran a personal best of 2:05.3 in the 800m while the stadium held nothing but her breathing and her footfalls. I called it a ghost chorus. Her coach later mentioned a silence drill — training without music or crowd noise. The empty stadium in Patiala taught me that silence can have a chorus. The silence in this case is the part with no team doctor, no TUE file, and nobody to tell the athlete to move the injection date.

The queue ahead: enforcement has moved to documents

Watch a pattern the statement does not contain but the surrounding cases do. A large share of AIU road-running cases are those where an initial substance violation is compounded by a fabricated explanation. That is not coincidence. It shows the enforcement frontier has shifted from detection to document verification — the agency now checks whether your explanation is true, not only whether your sample is clean.

Which means more cases are likely coming, because the same informal medical network serves many athletes in the same training cluster. Where a prescription was produced for one athlete, it can be produced for another.

The second consequence is that China's label circuit will carry rising integrity risk. Large appearance-fee budgets, deep East African fields and AIU testing now meet in the same event. That is a question for organisers, not only athletes.

The contrarian read: six years is for paperwork, not for medicine

The received story is simple: a runner got caught, showed fake paper, got six years. Reports called it a "prohibited steroid," which let the whole case snap into a familiar shape — and in that shape the punishment looks proportionate.

But the numbers refuse that shape. The substance at the centre of this ban has no proven endurance performance benefit. A glucocorticoid reduces pain and inflammation; it is not the thing that moves a runner from 2:20 to 2:18. So this is not a six-year sentence for an advantage gained. Four of those years are for paperwork, and two for a residue that a lawful treatment could also have left.

The real irony sits here: the one defence that could have worked was the true one, and it was destroyed by inventing a false one. The system did not catch a clever cheat; it caught a bad forger. Those are different stories, and the second one raises the question of why the process that needed protecting became the main basis of the punishment.

This is not a defence of forgery, and that should be said plainly. Four years for tampering is correct — fabricated evidence attacks a system that must stay identical for everyone. But when you read the case as "steroid caught," the sanction feels right; when you read it as "glucocorticoid residue whose defence was destroyed by fake paper," you ask what the sanction landed on. Answer: not the medicine, the paper. And that paper was written by someone with no medical registration, because there was no registered physician within reach.

The second reversal is the one that unsettles me most. The romantic story of the small-town underdog convinces us that struggle is the real story. In marathon, it is not struggle but medical administration. An athlete with a credentialed team physician, a TUE file and a coordinator who keeps the injection date away from race day never reaches this point. The sanction fell on the one who had none of the three. That inequality sits under the story we walk past, calling it a win for clean sport.

What comes next

The AIU is building the enforcement layer. Nobody is building the compliance layer where an athlete without the budget for a team doctor can learn which date to schedule a knee injection. The forged-prescription incident will happen again, because the absence at its root has not been filled.

The next Ruti Aga is training somewhere right now. And we already know what the first sentence about her will be in five years — unless someone learns her name, pronounced correctly, before that.